Silence Therapeutics (SLN) Cost of Revenue (2020 - 2026)
Silence Therapeutics recorded quarterly Cost of Revenue of $11000.0 in Q1 2026, down 8.33% quarter-over-quarter from $12000.0 in Q4 2025, and down 79.63% year-over-year from $54000.0 in Q1 2025.
Silence Therapeutics' Cost of Revenue history runs 7 years deep, the most recent figure standing at $11000.0 for Q1 2026.
- In Q1 2026, Cost of Revenue fell 79.63% year-over-year to $11000.0; the TTM figure through Mar 2026 stood at $172000.0 (down 98.1% YoY), while the FY2025 annual figure was $215000.0, down 98.18% from the prior year.
- Cost of Revenue came in at $11000.0 for Q1 2026 at Silence Therapeutics, down from $12000.0 in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $5.5 million in Q1 2023 to a low of $11000.0 in Q1 2026.
- A 5-year average of $2.2 million and a median of $2.8 million in 2024 frame the typical range for Cost of Revenue.
- On a YoY basis, Cost of Revenue climbed as much as 143934.84% in 2022 and fell as far as 100.0% in 2022.
- Silence Therapeutics' Cost of Revenue stood at $4.5 million in 2022, then sank by 63.09% to $1.7 million in 2023, then grew by 21.99% to $2.0 million in 2024, then sank by 99.41% to $12000.0 in 2025, then declined by 8.33% to $11000.0 in 2026.
- According to Business Quant data, Cost of Revenue over the past three periods registered $11000.0, $12000.0, and $64000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 64.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 392.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 296.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 207.52 Mn |
| 10 | Silence Therapeutics | 924.61 Mn | 854.53 Mn | 411,000.00 | 11,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11,000.00 |
| Mar 31, 2026 | 11,000.00 |
| Dec 31, 2025 | 12,000.00 |
| Dec 31, 2025 | 12,000.00 |
| Sep 30, 2025 | 64,000.00 |
| Sep 30, 2025 | 64,000.00 |
| Jun 30, 2025 | 85,000.00 |
| Jun 30, 2025 | 85,000.00 |
| Mar 31, 2025 | 54,000.00 |
| Mar 31, 2025 | 54,000.00 |
| Dec 31, 2024 | 2.04 Mn |
| Dec 31, 2024 | 2.04 Mn |
| Sep 30, 2024 | 3.64 Mn |
| Sep 30, 2024 | 3.64 Mn |
| Jun 30, 2024 | 3.33 Mn |
| Jun 30, 2024 | 3.33 Mn |
| Mar 31, 2024 | 2.80 Mn |
| Mar 31, 2024 | 2.80 Mn |
| Dec 31, 2023 | 1.67 Mn |
| Dec 31, 2023 | 1.67 Mn |
| Sep 30, 2023 | 2.04 Mn |
| Sep 30, 2023 | 2.04 Mn |
| Jun 30, 2023 | 3.54 Mn |
| Jun 30, 2023 | 3.54 Mn |
| Mar 31, 2023 | 5.51 Mn |
| Mar 31, 2023 | 5.51 Mn |
| Dec 31, 2022 | 4.53 Mn |
| Dec 31, 2022 | 4.53 Mn |
| Sep 30, 2022 | 2.82 Mn |
| Sep 30, 2022 | 2.82 Mn |
| Jun 30, 2022 | 2.96 Mn |
| Jun 30, 2022 | 2.96 Mn |
| Mar 31, 2022 | 3.05 Mn |
| Mar 31, 2022 | 3.05 Mn |
| Dec 31, 2021 | -7,298.12 Bn |
| Dec 31, 2021 | -7,298.12 Bn |
| Sep 30, 2021 | 2.83 Mn |
| Sep 30, 2021 | 2.83 Mn |
| Jun 30, 2021 | 2,550.85 Bn |
| Jun 30, 2021 | 2,550.85 Bn |
| Mar 31, 2021 | 2,119.40 |
| Mar 31, 2021 | 2,119.40 |
| Dec 31, 2020 | 4.96 Mn |
| Dec 31, 2020 | 4.96 Mn |
| Sep 30, 2020 | 3,008.16 |
| Sep 30, 2020 | 3,008.16 |